ngiotensin II (Ang II) is an octapeptide hormone that plays a central role in cardiovascular homeostasis. Typical of many proteins, Ang II was named on the basis of its first-demonstrated biological function-the ability to act as a vasoactive agonist and induce contraction of blood vessels. Over the years, Ang II has been shown to play important roles in mediating hypertension, heart failure, cardiac remodeling, diabetes, and the proliferative and inflammatory responses to arterial injury (see review 1 ). These findings have spawned the development of several classes of pharmacological agents designed at inhibiting the synthesis of Ang II (eg, angiotensin II-converting enzyme inhibitors) or blocking its action (eg, angiotensin II receptor antagonists). These agents are now widely used in the treatment of hypertension and congestive heart failure.
In conjunction with studies performed on animal models, there have been numerous studies examining the cellular effects of Ang II. Initial studies focused in particular on the role of Ang II as a contractile agonist and therefore on the signals induced by Ang II in vascular smooth muscle cells (SMCs) and cardiomyocytes associated with contraction, such as the mobilization of intracellular calcium ([Ca 2ϩ ] i ) and the activation of protein kinase C (PKC). It was demonstrated that Ang II activated phospholipase C, resulting in the production of inositol trisphosphate (IP 3 ) and diacylglycerol, which in turn were responsible for the mobilization of [Ca 2ϩ ] i and the activation of PKC, respectively. Additional studies in SMC cultures examined the properties of Ang II as a growth agonist, in particular its role in promoting cellular hypertrophy, characterized by increases in protein synthesis, cell size, and polyploidy. 2, 3 The cloning and expression of the Ang II receptor, 4,5 together with substantial progress in signal transduction, have greatly expanded our knowledge of Ang II-mediated cellular events and have led to a complex model in which Ang II stimulates the production of reactive oxygen species and activates a myriad of intracellular signals, including the mitogen-activated protein kinase, phosphatidylinositol 3-kinase/Akt, and JAK/STAT pathways (see reviews 6, 7 ). The diversity of Ang II-activated signaling strongly suggests that Ang II serves a multiplicity of functions distinct from its ability to promote contraction or induce cellular hypertrophy. Because many of these signals are known to be involved in regulating transcription, a logical approach to studying Ang II biology has been to identify genes regulated by Ang II.
Initial studies on identifying Ang II-responsive genes were in part driven by the evolving understanding of the roles of [Ca 2ϩ ] i and PKC as upstream mediators of gene transcription and in part by the known role of Ang II in cell growth. The focus of these studies was on SMCs, the major contractile cells of the blood vessel wall. In culture, SMCs modulate from a quiescent, contractile phenotype associated with abundant actin-and myosin-containing filaments to a synthetic phenotype in which the contractile filaments have been largely replaced by endoplasmic reticulum. 8 This phenotypically modulated SMC is similar in many respects to fibroblasts. It was therefore not surprising that a candidate gene approach focused on genes previously shown to be regulated by Ca 2ϩ and PKC in cultured fibroblasts. These early studies demonstrated that Ang II induced c-fos, c-jun, and c-myc, proto-oncogenes that encode transcription factors that act in part as mediators of cell growth and differentiation (see review 9 ). Additional studies using the candidate gene strategy determined that Ang II induced tissue factor, the initiator of coagulation and plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis. This raised the possibility that Ang II could promote a procoagulant state, such as that associated with myocardial infarction, stroke, and peripheral arterial occlusive disease (see review 10 ). Ang II was also shown to induce JE/MCP-1, interleukin-6, and KC/gro, chemokines that are important in recruiting leukocytes to sites of inflammation, thereby implicating Ang II as a proinflammatory molecule (see review 11 ).
The success of signaling studies and candidate gene approaches in establishing Ang II as a broad-based cellular agonist has provided the impetus to undertake more comprehensive analyses of Ang II effects on gene induction. Several studies using the then state-of-the-art technique of differential hybridization identified lysyl oxidase, lactate dehydrogenase, osteopontin, thrombospondin, and an intracellular prolyl hydroxylase, originally designated as SM-20, as Ang II-responsive genes, further broadening the potential biological roles of Ang II, particularly in regard to modulating the extracellular matrix. 12, 13 The study by Campos et al 14 in this issue of Circulation Research has used the current state-of-the-art technology, DNA microarray, to provide the most comprehensive analysis of Ang II-mediated gene induction to date. This study used a microarray containing 5088 genes and expressed sequence tags (ESTs) to examine cultured rat aortic SMCs treated with Ang II. As befitting any study using microarrays, considerable effort was expended on establishing the reproducibility of the system and on the data analysis, with several approaches used to ensure reasonable sensitivity and specificity. By t test, 91 genes were found to be regulated by Ն1.5-fold by Ang II, whereas 97 genes were identified using the rank sum test. Many of these genes represent ESTs whose identities have not yet been established. In addition, a variety of genes not previously known to be Ang II-sensitive were identified, including calpactin I light chain and calpactin II, whose regulation by Ang II was confirmed by quantitative real-time PCR. This study has therefore greatly expanded the database of Ang II-responsive genes and will likely provide new insights into the biological roles of Ang II in smooth muscle. The present study used an array of Ϸ5000 genes and ESTs, representing no more than 10% of the SMC transcripts. It is therefore likely that a screen representing the entire genome would have yielded close to 1000 Ang II-regulated genes.
Although the microarray approach identified several genes previously shown to be induced by Ang II, such as osteopontin, lactate dehydrogenase, and PAI-1, other Ang II-responsive genes, such as tissue factor, MCP-1, and c-fos, were not identified by this method. One relatively straightforward explanation is that these DNAs were not included in the microarray and would have been readily identified using a different array. More problematic however are the limitations posed by the SMC culture system. This study used rat aortic SMCs between passages 4 and 16. Postconfluent cells were incubated with 300 nmol/L of Ang II or vehicle for 6 hours. As discussed by the authors, 20 microarrays (11 control and 9 Ang II-treated) were required to provide statistically significant results. Even at this sample size, it was predicted that only 96% and 61% of the genes regulated by Ն2.0-fold or Ն1.5-fold by Ang II could be identified. Twenty-eight control-Ang II sets would have been necessary to identify all of the genes regulated by Ն2.0-fold. Even using the less stringent requirements, it is impractical to use more than a few conditions to examine gene induction. The 6-hour treatment time point would not have been expected to identify early-response genes such as tissue factor, c-fos, or c-jun. Given the wealth of information on early-response genes and the relative lack of information on delayed-response genes, the 6-hour point chosen for the present study had a greater likelihood of providing novel information.
Another important choice in this study was the use of postconfluent multiple-passaged cultured cells. As noted earlier, cultured SMCs undergo phenotypic modulation to a proliferative and more dedifferentiated phenotype. As such, they are not highly representative of the quiescent, contractile SMCs found in the normal arterial wall. Unfortunately, there has been no reliable method to induce differentiation of cultured SMCs back to the contractile phenotype. One compromise has been to study cells at postconfluence under conditions in which they are relatively quiescent, as done in the present study. Such an approach also has the benefit of better reproducibility. A second approach would be to examine SMCs in primary culture, before passaging, or at the very earliest passages. Although these cells are presumably less modulated, the limitations on quantity at such early stages of culture, necessitating multiple preparations, and the vicissitudes of primary culture would likely create insurmountable problems with reproducibility.
A major concern of SMC biologists is whether studies using cell culture can be extrapolated to the normally quiescent and contractile cells of the intact arterial wall. It is likely that at least some of the genes identified by microarray technology using Ang II-treated cultured SMCs will not be responsive to Ang II in vivo. On the other hand, studies using models of arterial injury have provided strong corroboration for many cell culture studies. In response to arterial injury, SMCs undergo phenotypic modulation similar to that seen in culture. 15 The proliferation and migration of SMCs are critical to the development of intimal hyperplasia in response to injury and are also key features of atherosclerotic plaque formation. 16, 17 A variety of SMC agonists, including plateletderived growth factor (PDGF), fibroblast growth factor, and Ang II, have been implicated as mediators of intimal hyperplasia. 18, 19 In addition, the pattern of gene induction in arterial SMCs after acute arterial injury is similar to that seen in cultured SMCs treated with growth agonists, such as Ang II and PDGF. Several of the genes identified by the current microarray analysis have previously been shown to be inducible by arterial injury, including osteopontin, 20 PAI-1, 21 and tissue inhibitor of metalloproteinase-1 (TIMP-1). 22 The present study used a well-established model of balloon injury to rat carotid arteries to demonstrate that calpactin I light chain is also induced in vivo. It is likely that other genes identified in this screening will be shown to be modulated similarly and may provide new insights into the molecular events associated with arterial injury, whether or not mediated in vivo by Ang II.
Although DNA microarray technology provides a powerful tool to understanding the protean manifestations of Ang II, it is likely that the results of such studies, no matter how comprehensive, will provide only a partial picture of the effects of Ang II on SMCs. As noted above, Ang II is a potent inducer of protein synthesis and activates a variety of kinases that are capable of posttranslational modifications (see reviews 6,7 ). One would therefore expect that Ang II would modulate the amount or activity of a number of proteins independent of its effects on transcription. Such changes will require a proteomics-based approach. One such approach, reported by Patton et al, 23 used two-dimensional gel electrophoresis to identify proteins phosphorylated in response to Ang II and PDGF. This approach identified a dozen proteins regulated by Ang II, including molecular chaperones and those involved with protein folding. These proteins were not overlapping with those found using RNA-based technologies, nor were they identified as yet in the current microarray analysis. In the same way that microarray techniques provide considerably more power than the early DNA hybridization studies, recent advances in proteomics should also provide far more powerful approaches to identifying proteins modulated by Ang II. Together with genomics, this should provide a comprehensive picture of the effects of Ang II on cellular function and further support the notion that the term "angio-
